Literature DB >> 11721619

Hot topics in adeno-associated virus as a gene transfer vector.

N Zhao1, D P Liu, C C Liang.   

Abstract

Adeno-associated virus (AAV) is a promising viral vector in treating many kinds of hereditary diseases. The broad host range, low level of immune response, and longevity of gene expression observed with this vector have enabled the initiation of a number of clinical trials using this gene delivery system. Another potential benefit of AAV vectors is their ability to integrate site-specifically in the presence of Rep proteins. However, this virus is not well characterized. To obtain high level, persistent expression of the foreign gene, some problems should be solved. In this article, we will describe the advances in some fields of recombinant AAV technology that overcome certain limitations of the vector as a gene delivery system, such as the transduction efficiency, the production, the package capacity, and elimination of immune responses, as well as the applications involving these recombinant vectors for the treatment of some diseases.

Entities:  

Mesh:

Year:  2001        PMID: 11721619     DOI: 10.1385/MB:19:3:229

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  55 in total

1.  Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.

Authors:  X L Liu; K R Clark; P R Johnson
Journal:  Gene Ther       Date:  1999-02       Impact factor: 5.250

2.  Left of what? The role of egocentric coordinates in neglect.

Authors:  N Beschin; R Cubelli; S Della Sala; L Spinazzola
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Factors influencing recombinant adeno-associated virus production.

Authors:  A Salvetti; S Orève; G Chadeuf; D Favre; Y Cherel; P Champion-Arnaud; J David-Ameline; P Moullier
Journal:  Hum Gene Ther       Date:  1998-03-20       Impact factor: 5.695

5.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system.

Authors:  T Ueno; H Matsumura; K Tanaka; T Iwasaki; M Ueno; K Fujinaga; K Asada; I Kato
Journal:  Biochem Biophys Res Commun       Date:  2000-07-05       Impact factor: 3.575

7.  Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry.

Authors:  R Bals; W Xiao; N Sang; D J Weiner; R L Meegalla; J M Wilson
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Selective cleavage of AAVS1 substrates by the adeno-associated virus type 2 rep68 protein is dependent on topological and sequence constraints.

Authors:  S Lamartina; G Ciliberto; C Toniatti
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors:  A Girod; M Ried; C Wobus; H Lahm; K Leike; J Kleinschmidt; G Deléage; M Hallek
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

10.  Adeno-associated virus as a vector for liver-directed gene therapy.

Authors:  W Xiao; S C Berta; M M Lu; A D Moscioni; J Tazelaar; J M Wilson
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  4 in total

Review 1.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.

Authors:  C Jenny; E Toublanc; O Danos; O-W Merten
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

Review 3.  Local drug and gene delivery through microbubbles and ultrasound.

Authors:  L J M Juffermans; P A Dijkmans; R J P Musters; A van Wamel; A Bouakaz; F J Ten Cate; L Deelman; C A Visser; N de Jong; O Kamp
Journal:  Neth Heart J       Date:  2004-09       Impact factor: 2.380

4.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.